- Conditions
- Advanced Liver Cancers
- Interventions
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 16
- States / cities
- Costa Mesa, California • Duarte, California • Orange, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 389
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Group B Streptococcal Infections
- Interventions
- IVT GBS-06, Placebo
- Biological
- Lead sponsor
- Inventprise Inc.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumours
- Interventions
- AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 6
- States / cities
- Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
- Conditions
- Lymphoma
- Interventions
- RP4010
- Drug
- Lead sponsor
- Rhizen Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 4 more
- Conditions
- Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
- Interventions
- Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- Sunitinib, Regorafenib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye Cancer
- Interventions
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Drug
- Lead sponsor
- Novelwise Pharmaceutical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
- Conditions
- Cutaneous T Cell Lymphoma
- Interventions
- Placebo, CD11301 0.03%, CD11301 0.06%
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 11
- States / cities
- Orange, California • Palo Alto, California • Farmington, Connecticut + 7 more
- Conditions
- Stage IB-IIIA Non-small Cell Lung Carcinoma
- Interventions
- AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
- Interventions
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
- Procedure · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Acute Myeloid Leukemia
- Interventions
- AZD1208
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Houston, Texas
- Conditions
- Breast Cancer, Cancer Survivor, Fatigue, Pain
- Interventions
- exercise intervention, educational intervention, complementary or alternative medicine procedure, fatigue assessment and management, management of therapy complications, pain therapy, quality-of-life assessment
- Behavioral · Other · Procedure
- Lead sponsor
- Clayton State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Morrow, Georgia
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- IPN60300
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more
- Conditions
- Myelofibrosis
- Interventions
- Placebo, Ruxolitinib, Vismodegib
- Other · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 3 more
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg, Peposertib 250 mg, Capecitabine, Radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more
- Conditions
- Advanced Solid Tumours, Small Cell Lung Cancer
- Interventions
- IMP4297(senaparib)
- Drug
- Lead sponsor
- Impact Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Evergreen Park, Illinois • Canton, Ohio • Columbus, Ohio + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- LDE225, Wafarin, Bupropion
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 13
- States / cities
- Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
- Interventions
- Enzelkitug, Atezolizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 10
- States / cities
- San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more
- Conditions
- White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
- Interventions
- Clemastine fumarate
- Drug
- Lead sponsor
- Bridget LaMonica Ostrem, M.D., Ph.D.
- Other
- Eligibility
- 3 Weeks to 20 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Melanoma
- Interventions
- IN10018, Cobimetinib, Atezolizumab
- Drug · Biological
- Lead sponsor
- InxMed (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
- Drug
- Lead sponsor
- Adagene Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
- Conditions
- Stage IV Non-Small Cell Lung Cancer
- Interventions
- Cetuximab in combination with Carboplatin/Gemcitabine
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
- Interventions
- Fragmin, placebo
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neoplasms
- Interventions
- GSK3052230, paclitaxel, carboplatin, docetaxel, pemetrexed, cisplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- Duarte, California • Sacramento, California • Chicago, Illinois + 7 more